Chemotherapy administered to a case of non-resectable advanced gastric cancer with esophageal invasion and bone metastasis was found to be remarkably effective over two years and 4 months. For imaging investigation, the efficacy of the chemotherapy was judged to be a partial response (PR), Furthermore, DNA histograms prepared by flow cytometry as a diagnostic test for malignancy of cancer revealed changes in the primary lesion from an aneuploidy pattern to a diploidy pattern concomitant with the administration of chemotherapy. Since non-phasic metastasis to the cerebellum and the adrenals were detected subsequently, intensive therapy consisting of radical gastric resection, left adrenal resection and deep cerebellur nucleus resection combined with radiotherapy, was conducted with the objective of prolonging the survival of the patient. The total course extended for about 4 years and considering the stage of advanced cancer, we believe that a favorable quality of life (QOL) was achieved based on the Performance status (P. S) level, maintenance of a satisfactory level of meal consumption, continuation of employment at times other than hospital admission and a home-residence rate of 72.3 per cent.
Introduction
The effectiveness of chemotherapy for non-resectable gastric cancer accompanied by distant metastasis is poor (MacDonalds, Philip et al., 1980; Wolly, Smithet al., 1981; Preusser, Wilke et al., 1987) . In addition, various other associated problems, such as long-term hospital admission and Performance Status reduction, impose difficulties on the achievement of a favorable quality of life (QOL) (Takahashi and Nishioka, 1995) .
However, the only criteria for evaluating the efficacy of chemotherapy are the findings of imaging investigations, which do not reflect the degree of malignancy of cancer, and the judgment of chemotherapy efficacy and the survival time are not necessarily correlated.
We experienced a case in whom chemotherapy was effective not only in terms of tumor imaging but also in favorable QOL with satisfactory long-term levels of P. S, meal intake and a home residence rate and flow cytometric analysis of DNA histogram (Sasaki and Ogino, 1986; Danova, Mazzini et al., 1987) obtained from the tumor tissue showed improvement of the degree of malignancy as the improvement of the disease. 
Case Report
The patient was a 38-year-old man who had dyspeptic symptoms after eating. Gastric cancer of the cardia was presumptively detected by barium meal study at a medical check ANNALS OF Cancer Research and Therapy (Figures 7a, 7b, 7c ). The patient had been scheduled to be discharged from hospital in November 1994.
However, the patient began to manifest a severe headache, and the values for the tumor marker, CEA, increased again, from 10.8 to 46.3ng/ml. As the brain CT performed at that time revealed a small brain metastasis, his discharge was postponed and he underwent intensive therapy, including tumor extirpation and radiotherapy at the Neurosurgery and Radiology Departments of our hospital. Regardless of such therapies, he died of cachexia 18 months after the surgical laparotomy (survival time 1420 days).
Discussion
Non-resectable advanced gastric cancers accompanied by distant metastasis are treated by a variety of therapies, including systemic chemotherapy with combined multiple drugs (MacDonalds, Philip et al., 1980; Wolly, Smith et al., 1981; Preusser, Wilke et al., 1987) and immunotherapy (Mizumoto, Ohoue et al., 1989) . However, outcome in such diseases has not been still satisfactory. There has been a recent trend in Japan toward an increase of cases in whom systemic chemotherapy for gastric cancer was effective to some extent.
Nevertheless, there have been few reports (Nakata, Shigemitsu et al., 1985; Ono, Ishikawa et al., 1994; Tsuji, Suematsu et al., 1994; Iwazaki, Okura et al., 1994; Iwazaki, Maehiro et al., 1996) documenting remarkable effectiveness of systemic chemotherapy in advanced gastric cancers. Moreover, complete response to the chemotherapy was not histologically confirmed in most of such cases. As to patients showing marked improvement of advanced gastric cancer by chemotherapy (Kurihara, Izumiet al., 1977; Tokimatsu, Yasutake et al., 1989) In our case, patients of 38 years old was in good general condition, type 2 gastric cancer with esophageal invasion and bone metastasis, and that the patient with a tumor that was a histopathologically poorly differentiated type of adenocarcinoma. However, the primary cancer and metastatic lesions were found to be remarkably decreased in size and denatured by chemotherapy (UFTMP therapy) (Iwazaki, Yasutake et al., 1993) of two courses.
At the present time, since the efficacy of chemotherapy are evaluated only by morphological of images investigations that do not reflect the biological malignant degree of tumors, efficacy of chemotherapy and the survival time (Takahashi and Nishioka, 1995) are not necessarily closely correlated. The rate and capacity of proliferation of a cancer are considered to be predicting factors for biological malignant degree. Recently, immunostaining technique (Sasaki and Ogino, 1986; Danova, Mazzini et al., 1987; Hoshino, Prados et al., 1989; ROBBINS, Vega et al., 1987; Ploton, Menager et al., 1986; Crocker, 1990; Gerdes, Lemke et al., 1984; Lowe, Bodis et al., 1994; James, Richard et al., 1986; Korenaga, Okamura et al., 1988; Olga and Galina, 1998; Saito, Korenaga et al., 1991) that employs an antibody specific to an antigen (proliferating cell antigen), and is closely associated with the cell proliferation activity, have become available for predicting factors for proliferative capacity of a tumor. These markers includes BrdU (bromodeoxyuridine) (Hoshino, Prados et al., 1989) , PCNA (proliferating cell nuclear antigen) (Robbins, Vega et al., 1987) , AgNORs (Ploton, Menager et al., 1986; Crocker, 1990) , Ki67 (Gerdes, Lemke et al., 1984) , DNA histograms produced by flow cytometry (Sasaki and Ogino, 1986; Danova, Mazzini et al., 1987) or oncogenes, such as p53 (Lowe, Bodis et al., 1994) . 
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Analysis of the degree of malignancy of gastric cancer using a DNA histogram obtained by flow cytometry has shown that an aneuploidy DNA pattern is common in tumors that show a high level of cell proliferative activity, frequent lymph node metastasis and an especially marked tendency for deep-site infiltration (James, Richard et al., 1986; Korenaga, Okamura et al., 1988; Olga and Galina, 1998) . In aspect of the tissue type of gastric cancers, it has been shown that there is a tendency that undifferentiated types have a rather higher level of susceptibility to anti-cancer agents than differentiated types (Saito, Korenaga et al., 1991) . It has also been reported that poorly differentiated types with an aneuploidy pattern show a higher level of susceptibility to anti-cancer agents than differentiated types by analyzes of DNA histograms obtained by flow cytometry (Maehara, Anai et al., 1987) .
In our case, biopsy specimens yielded negative immunostaining results for the oncogene, p53. Accordingly, we considered that p53 was normal, and we could not technically detect a mutants of p53. The DNA histogram obtained by flow cytometry in this case revealed an aneuploidy pattern, which had shown a diploidy DNA pattern concomitant with the course of remarkably effective chemotherapy. As a result, in spite of the fact that this was a case of non-resectable advanced gastric cancer, the treatment was remarkably effective with a favorable QOL (Takahashi and Nishioka, 1995) evaluated on the basis of long-term satisfactory P. S, meal intake levels, high rate of home residence for 2 years and a relatively long period until the appearance of adrenal metastasis.
Intensive therapy include chemotherapy should be performed with a case of this type.
This active strategy may enable a better outcome to be achieved not only in terms of tumor imaging, but also in favorable QOL with satisfactory long-term levels of P. S, meal intake and a home residence rate.
In the future, we have to randomize comparisons of phase III study of chemotherapy with the use of best supportive care (BSC) alone in patients with non-resectable gastric cancer (Glimelius, 1994; Pyrhonen, 1995) .
